Classifications

• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
  • G01N33/54366—Apparatus specially adapted for solid-phase testing
  • G01N33/54373—Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
  • G01N33/5438—Electrodes
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
  • G01N33/54366—Apparatus specially adapted for solid-phase testing
  • G01N33/54386—Analytical elements
  • G01N33/54387—Immunochromatographic test strips
  • G01N33/54388—Immunochromatographic test strips based on lateral flow

Definitions

• Affinity assays are widely used in medical, food, and environmental research and are based on the principle of a reagent binding to a target analyte. The binding interaction is detected through some physico-chemical change, the magnitude of which is proportional to the analyte concentration.
• Many different reagents have been described including, but not limited to, antibodies, other proteins, nucleic acids, and synthetic receptors.
• Antibodies are commonly used as the reagent and many different assay formats using antibodies have been described. These are collectively referred to as immunoassays.
• One type of immunoassay which is particularly suitable for point of care tests (POCTs) is the lateral flow (LF) immunoassay (also referred to as an immunochromatographic assay).
• LF lateral flow
• LF immunoassays are a well-established and robust technology for detection of antigens. They are adapted to operate along a single axis to suit a test strip format and typically employ a sandwich (also referred to as 2-site, reagent excess or non-competitive) format. In this format one of two antibodies is labelled, typically with coloured particles, and dried as a soluble preparation on a LF membrane (typically a hydrophobic nitrocellulose or cellulose acetate membrane). This first antibody dissolves in the sample, whilst a second antibody is fixed to the LF membrane some short distance from the first antibody. Sample solution carries the first antibody to the second through capillary flow and the immune complex that forms during this flow is captured by the second antibody forming a visible line. Excess labelled first antibody is carried past this 'test line' to react at a control line. This provides a qualitative read-out.
• apparatus for the quantitative analysis of an analyte in a sample comprises:
• the surface of the solid phase comprises:
• a first molecule that binds to the analyte and is capable of releasing a detectable species is either deposited on the solid phase or is added to the sample prior to application to the solid phase, and
• the detector is located in close proximity to the immobilised molecule at the second position.
• a method for quantitative detection of target molecules in a substrate-containing sample comprises:
• step b) applying the complex formed in step a) to a solid phase, wherein the surface of the solid phase comprises:
• detection of said species is proportional to the target molecule content of the sample.
• the apparatus described in the first aspect of the invention is used in the method for quantitative detection of target molecules in a substrate-containing sample according to the second aspect of the invention.
• Figure 1 is a schematic representation of the amplified electrochemical lateral flow (LF) test strip
• Figure 2 is a schematic representation of the amplified electrochemical reaction
• Figure 3 is a graphical representation of the pH change as a function of the enzymatic reaction between urease and urea in a 2mM Tris/HCI buffer solution;
• Figure 4 is a graphical representation of the pH change as a function of the enzymatic reaction between pyrophosphate and pyrophosphatase in a solution with a low buffering capacity (2mM Tris/HCI buffer with addition of 2mM MgCI 2 );
• Figure 5 is a graph showing the effect of increasing the local pH on release of a first encapsulated label
• Figure 6 shows a similar effect to Figure 5 but using potassium ferricyanate as the first label rather than ferrocene carboxylic acid;
• Figure 7 shows the production of current as a function of ferrocene carboxylic acid release from polymeric bead at different time points.
• the present invention addresses the aims of increasing the sensitivity of binding assays and is described in detail with reference to the lateral flow (LF) immunoassay.
• the invention provides a quantitative numerical readout of the amount of immune complex present in a sample, whilst retaining the simplicity and robustness of the assay format, by replacing the visual estimation of immune complex formation with an electrochemical measurement.
• SERRS encapsulated surface enhanced resonance Raman scattering
• the invention provides an apparatus for the quantitative analysis of an analyte in a sample, comprising:
• the surface of the solid phase comprises:
• a first molecule that binds to the analyte and is capable of releasing a detectable species is either deposited on the solid phase or is added to the sample prior to application to the solid phase, and
• the detector is located in close proximity to the immobilised molecule at the second position.
• distal from means that the second position is not immediately adjacent to the first position.
• the second position is located downstream from the first position in the direct of flow.
• the term "close proximity" means that the detector must be positioned sufficiently close to the immobilized molecule at the second position to be able to detect any change in current or charge passed at said second position.
• the detector is located as close as possible to the immobilized molecule at the second position.
• the solid phase may be any suitable solid material or membrane, such as porous and/or non-porous surfaces such as silicon, silicon oxide, metallic and metal-coated surfaces, polymeric and polysaccharide surfaces.
• the solid phase is a lateral flow (LF) membrane, preferably comprising chromatogenic media, which may be polymeric or cellulosic, such as hydrophobic nitrocellulose or cellulose acetate.
• the present invention also provides a method for quantitative detection of target molecules in a substrate-containing sample.
• the method comprises the following steps:
• step b) applying the complex formed in step a) to a solid phase, wherein the surface of the solid phase comprises:
• detection of said species is proportional to the target molecule content of the sample.
• the target molecule is an antigen and the first and second labelled binding molecules are antibodies.
• the complex formed is an immune complex.
• Step (c) may take place as the complex is transported to the second position.
• Such transportation may be by means of capillary action, microfluidics or electrophoretic migration.
• the apparatus described in the first aspect of the invention can be used in the method for quantitative detection of target molecules in a substrate-containing sample according to the second aspect of the invention.
• the method utilises the presence of substrate in the sample to change the local pH at the test line through the co-deposition of a corresponding enzyme immobilized at the second position.
• a corresponding enzyme to refer to an entity that catalysis the chemical reaction with a given substrate.
• the first label that is capable of releasing a detectable species is preferably a redox probe, and is preferably encapsulated in a polymer.
• the polymer may be an enteric coating material which dissolves when subjected to a pH change, typically under alkaline conditions, or alternatively it may be a 'smart' stimuli responsive polymer that swells in response to a pH change.
• Suitable enteric polymers include polyvinyl acetate phthalate, hydroxypropyl methylcellulose phthalate, methacrylic acid, cellulose acetate trimellitate, carboxymethyl ethylcellulose and hydroxypropyl methylcellulose acetate succinate.
• Suitable pH-responsive 'smart' polymers include poly(propylacrylic acid) and chitosan.
• Suitable redox probes undergo fast, preferably diffusion-limited, electron exchange at the detector and include complexes of iron, osmium, copper and ruthenium, as well as organic molecules such as flavins and dyes.
• ferrocene and its derivatives include but are not limited to: ferrocene and its derivatives; iron complexes such as hexacyanide; ruthenium complexes such as hexamine; osmium complexes as tris(bipyridyl); thiazine dyes; phenazine dyes; riboflavin and its derivatives; and tetrathiafulvalene and its derivatives. Additional examples will be apparent to those skilled in the art.
• the second binding molecule is preferably labelled with biotin and the molecule that binds to it, and which is immobilised at the second position, is preferably avidin or streptavidin.
• the detector located in close proximity to the immobilised molecule at the second position is preferably positioned below the test line (i.e. at or underneath the second position on the LF membrane).
• the detector is preferably an electrode, and preferably a screen printed electrode.
• the skilled person will be familiar with the term "screen-printed electrode". However, for the avoidance of doubt, this is defined as a conducting carbon ink or metal paste film deposited on an inert support, such as PVC, ceramic, and alumina or polyester, and incorporating reference and counter electrodes.
• the electrode is preferably poised at a potential where there is a diffusion-limited reduction of the redox probe and a minimal background current from the sample.
• the detector must be positioned in sufficiently close proximity to the immobilized molecule at the second position (i.e. the test line) to be able to detect the change in current or charge passed.
• the apparatus and method of the invention may be used for the in vitro quantitative analysis of many analytes including antigens, antibodies, other proteins and the products of nucleic acid amplification tests.
• the test sample may be selected from the following non-limiting group of body samples obtained from a subject or patient: urine; saliva; serum; plasma; whole blood; faeces; and exudates (e.g. from wounds or lesions).
• the sample may be a nonclinical material, such as soil, air, water or food matter.
• the apparatus and method of the invention can be used as a tool to aid diagnosis and patient management.
• the assay can be used to identify, confirm, or rule out disease in symptomatic patients, or to accurately prescribe therapeutic drugs and to monitor treatment, for example to monitor blood sugar levels in diabetic patients or to determine pregnancy.
• Other uses also include in epidemiology, where the rapid assay can be used to detect and monitor the incidence or prevalence of disease for targeting and evaluating health programs, as well as in screening to determine the prevalence of disease in asymptomatic individuals.
• 'subject' and 'patient' are used interchangeably herein and refer to a mammal including a non-primate (e.g. a cow, pig, horse, dog, cat, rat and mouse) and a primate (e.g. a monkey and human), and preferably a human.
• a non-primate e.g. a cow, pig, horse, dog, cat, rat and mouse
• a primate e.g. a monkey and human
• an embodiment of the invention as a lateral flow immunoassay wherein the first and second binding molecules are antibodies, the target analyte is an antigen and the solid phase is a lateral flow membrane.
• the two antibodies Upon addition of the substrate-containing sample, the two antibodies dissolve and form the immune complex which is carried by lateral flow to the test line.
• the immune complex travels with the liquid front and is captured at the test line by the reaction between the biotin component of the immune complex and avidin/streptavidin present in the test line.
• the substrate arrives at the test line there is a local change in pH due to the conversion of the substrate within the test sample. This may be a change to a more acidic environment (i.e. a decrease in pH) to a more alkaline environment (i.e. an increase in pH) depending upon the specific enzyme used.
• the substrate-containing sample is preferably urine and the corresponding enzyme is therefore preferably urease.
• the concentration of urea in urine is around 10-20 times the Km value for urease; therefore the enzyme will be running at its maximal rate.
• the change in pH results in the redox probe undergoing reduction and releasing the redox species, which is detected from the current (or charge passed) at the underlying electrode.
• the current resulting from the released redox species is proportional to the antigen content of the sample. Therefore, by measuring the current (or charge passed) at the electrode, the antigen content of the sample can be determined quantitatively.
• Figure 3 illustrates the pH change as a function of the enzymatic reaction between urease and urea in a solution with a low buffering capacity (2mM Tris/HCI buffer).
• the substrate-containing sample may be pyrophosphate and the corresponding enzyme is therefore preferably pyrophosphatase.
• Figure 4 illustrates the pH change as a function of the enzymatic reaction between pyrophosphate and pyrophosphatase in a solution with a low buffering capacity (2mM Tris/HCI buffer with addition of 2mM MgCI 2 ).
• FIG. 5 The effect of increasing the local pH on release of the first encapsulated label (a redox probe, specifically a ferrocene derivative) is illustrated in Figure 5.
• This graph shows the spectrophotometric determination of ferrocene carboxylic acid release from polymeric beads as a function of time, at an alkaline pH of 9. As can be seen from the control values, when the pH is maintained at a mildly acidic pH of 5 the polymer does not dissolve and there is no increase in absorbance.
• FIG. 6 illustrates a similar effect, however in this experiment the redox probe is potassium ferricyanate.
• the graph shows the spectrophotometric determination of release of the encapsulated probe from polymeric beads as a function of time, at an alkaline pH of 9. As can be seen from the control values, when the pH is maintained at a mildly acidic pH of 5 the polymer does not dissolve and there is no increase in absorbance.
• Figure 7 illustrates the production of current as a function of the ferrocene carboxylic acid release from the polymeric beads at different time points and at an alkaline test pH of 9 and a mildly acidic control pH of 5.
• the graph shows that at pH 9 more electro-active molecules were released from the polymer beads as a function of polymer dissolution at the elevated pH. This release is reflected in the increase of the detected current. No current increase was observed at pH 5.

Landscapes

• Health & Medical Sciences (AREA)
• Immunology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Molecular Biology (AREA)
• Biomedical Technology (AREA)
• Chemical & Material Sciences (AREA)
• Hematology (AREA)
• Urology & Nephrology (AREA)
• Biotechnology (AREA)
• Biochemistry (AREA)
• Cell Biology (AREA)
• Food Science & Technology (AREA)
• Medicinal Chemistry (AREA)
• Physics & Mathematics (AREA)
• Analytical Chemistry (AREA)
• Microbiology (AREA)
• General Health & Medical Sciences (AREA)
• General Physics & Mathematics (AREA)
• Pathology (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Apparatus Associated With Microorganisms And Enzymes (AREA)
• Investigating Or Analysing Biological Materials (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (2)

Family

ID=44586826

Family Applications (1)

Country Status (7)

Cited By (2)

Families Citing this family (3)

Citations (1)

Family Cites Families (11)

• 2011
  • 2011-07-19 GB GBGB1112395.7A patent/GB201112395D0/en not_active Ceased
• 2012
  • 2012-07-19 JP JP2014520730A patent/JP6053781B2/ja not_active Expired - Fee Related
  • 2012-07-19 WO PCT/GB2012/051733 patent/WO2013011323A2/en not_active Ceased
  • 2012-07-19 US US14/233,233 patent/US20140248642A1/en not_active Abandoned
  • 2012-07-19 DK DK12738592.0T patent/DK2734842T3/en active
  • 2012-07-19 EP EP12738592.0A patent/EP2734842B1/en active Active
  • 2012-07-19 ES ES12738592.0T patent/ES2567803T3/es active Active

Patent Citations (1)

Also Published As

Similar Documents

Legal Events